BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

203 related articles for article (PubMed ID: 24326003)

  • 1. Efficacy and Safety of Linagliptin in Black/African American Patients with Type 2 Diabetes: A 6-month, Randomized, Double-blind, Placebo-controlled Study.
    Thrasher J; Daniels K; Patel S; Whetteckey J; Woerle HJ
    Endocr Pract; 2014 May; 20(5):412-20. PubMed ID: 24326003
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [The efficacy and safety of linagliptin in elderly patients with type 2 diabetes: a pooled analysis of eight placebo-controlled clinical trials].
    Guo XH; Feng ZK; Xu LH
    Zhonghua Nei Ke Za Zhi; 2017 Aug; 56(8):588-594. PubMed ID: 28789492
    [No Abstract]   [Full Text] [Related]  

  • 3. Efficacy and safety of linagliptin in subjects with long-standing type 2 diabetes mellitus (>10 years): evidence from pooled data of randomized, double-blind, placebo-controlled, phase III trials.
    Lajara R; Aguilar R; Hehnke U; Woerle HJ; von Eynatten M
    Clin Ther; 2014 Nov; 36(11):1595-605. PubMed ID: 25236917
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and safety of linagliptin in Asian patients with type 2 diabetes mellitus inadequately controlled by metformin: A multinational 24-week, randomized clinical trial.
    Wang W; Yang J; Yang G; Gong Y; Patel S; Zhang C; Izumoto T; Ning G
    J Diabetes; 2016 Mar; 8(2):229-37. PubMed ID: 25753488
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor linagliptin in black/African American patients with type 2 diabetes: Pooled analysis from eight Phase III trials.
    Thrasher J; Kountz DS; Crowe S; Woerle HJ; von Eynatten M
    Postgrad Med; 2015 Jun; 127(5):419-28. PubMed ID: 25840727
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and safety of linagliptin to improve glucose control in older people with type 2 diabetes on stable insulin therapy: A randomized trial.
    Ledesma G; Umpierrez GE; Morley JE; Lewis-D'Agostino D; Keller A; Meinicke T; van der Walt S; von Eynatten M
    Diabetes Obes Metab; 2019 Nov; 21(11):2465-2473. PubMed ID: 31297968
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Linagliptin for patients aged 70 years or older with type 2 diabetes inadequately controlled with common antidiabetes treatments: a randomised, double-blind, placebo-controlled trial.
    Barnett AH; Huisman H; Jones R; von Eynatten M; Patel S; Woerle HJ
    Lancet; 2013 Oct; 382(9902):1413-23. PubMed ID: 23948125
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Linagliptin monotherapy in type 2 diabetes patients for whom metformin is inappropriate: an 18-week randomized, double-blind, placebo-controlled phase III trial with a 34-week active-controlled extension.
    Barnett AH; Patel S; Harper R; Toorawa R; Thiemann S; von Eynatten M; Woerle HJ
    Diabetes Obes Metab; 2012 Dec; 14(12):1145-54. PubMed ID: 22974280
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and safety of initial combination therapy with linagliptin and pioglitazone in patients with inadequately controlled type 2 diabetes: a randomized, double-blind, placebo-controlled study.
    Gomis R; Espadero RM; Jones R; Woerle HJ; Dugi KA
    Diabetes Obes Metab; 2011 Jul; 13(7):653-61. PubMed ID: 21410628
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Linagliptin as add-on to empagliflozin and metformin in patients with type 2 diabetes: Two 24-week randomized, double-blind, double-dummy, parallel-group trials.
    Tinahones FJ; Gallwitz B; Nordaby M; Götz S; Maldonado-Lutomirsky M; Woerle HJ; Broedl UC
    Diabetes Obes Metab; 2017 Feb; 19(2):266-274. PubMed ID: 27762093
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and safety of linagliptin as add-on therapy to insulin in Chinese patients with type 2 diabetes mellitus: A randomized, double-blind, placebo-controlled trial.
    Yang W; Xu X; Lei T; Ma J; Li L; Shen J; Ye B; Zhu S; Meinicke T
    Diabetes Obes Metab; 2021 Feb; 23(2):642-647. PubMed ID: 33074590
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and safety of linagliptin co-administered with low-dose metformin once daily versus high-dose metformin twice daily in treatment-naïve patients with type 2 diabetes: a double-blind randomized trial.
    Ji L; Zinman B; Patel S; Ji J; Bailes Z; Thiemann S; Seck T
    Adv Ther; 2015 Mar; 32(3):201-15. PubMed ID: 25805187
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Empagliflozin as Add-on Therapy in Patients With Type 2 Diabetes Inadequately Controlled With Linagliptin and Metformin: A 24-Week Randomized, Double-Blind, Parallel-Group Trial.
    Søfteland E; Meier JJ; Vangen B; Toorawa R; Maldonado-Lutomirsky M; Broedl UC
    Diabetes Care; 2017 Feb; 40(2):201-209. PubMed ID: 27913576
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Linagliptin plus metformin in patients with newly diagnosed type 2 diabetes and marked hyperglycemia.
    Ross SA; Caballero AE; Del Prato S; Gallwitz B; Lewis-D'Agostino D; Bailes Z; Thiemann S; Patel S; Woerle HJ; von Eynatten M
    Postgrad Med; 2016 Nov; 128(8):747-754. PubMed ID: 27684308
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy and tolerability of linagliptin added to a sulfonylurea regimen in patients with inadequately controlled type 2 diabetes mellitus: an 18-week, multicenter, randomized, double-blind, placebo-controlled trial.
    Lewin AJ; Arvay L; Liu D; Patel S; von Eynatten M; Woerle HJ
    Clin Ther; 2012 Sep; 34(9):1909-19.e15. PubMed ID: 22939034
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparative efficacy and safety of gemigliptin versus linagliptin in type 2 diabetes patients with renal impairment: A 40-week extension of the GUARD randomized study.
    Han SY; Yoon SA; Han BG; Kim SG; Jo YI; Jeong KH; Oh KH; Park HC; Park SH; Kang SW; Na KR; Kang SW; Kim NH; Jang Y; Kim B; Shin S; Cha DR
    Diabetes Obes Metab; 2018 Feb; 20(2):292-300. PubMed ID: 28719008
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Long-Term Efficacy and Safety of Linagliptin in a Japanese Population with Type 2 Diabetes Aged ≥ 60 Years Treated with Basal Insulin: A Randomised Trial.
    Araki E; Unno Y; Tanaka Y; Sakamoto W; Miyamoto Y
    Adv Ther; 2019 Oct; 36(10):2697-2711. PubMed ID: 31482511
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Risk of hypoglycaemia in people aged ≥65 years receiving linagliptin: pooled data from 1489 individuals with type 2 diabetes mellitus.
    Nauck M; Araki A; Hehnke U; Plat A; Clark D; Khunti K
    Int J Clin Pract; 2018 Oct; 72(10):e13240. PubMed ID: 30216648
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Linagliptin improved glycaemic control without weight gain or hypoglycaemia in patients with type 2 diabetes inadequately controlled by a combination of metformin and pioglitazone: a 24-week randomized, double-blind study.
    Bajaj M; Gilman R; Patel S; Kempthorne-Rawson J; Lewis-D'Agostino D; Woerle HJ
    Diabet Med; 2014 Dec; 31(12):1505-14. PubMed ID: 24824197
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and Safety of Linagliptin in 2681 Asian Patients Stratified by Age, Obesity, and Renal Function: A Pooled Analysis of Randomized Clinical Trials.
    Ning G; Bandgar T; Hehnke U; Lee J; Chan JCN
    Adv Ther; 2017 Sep; 34(9):2150-2162. PubMed ID: 28819835
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.